influenza
epidem
pandem
constant
threat
human
health
larg
gene
pool
influenza
virus
resid
divers
anim
reservoir
webster
et
al
thu
influenza
virus
novel
genet
composit
abl
emerg
genet
reassort
time
recent
seen
viru
smith
et
al
errorpron
rnadepend
rna
polymeras
laur
andino
influenza
viru
increas
divers
influenza
genom
random
mutat
increas
challeng
control
influenza
infect
southeast
asia
long
term
epicentr
influenza
viru
shortridg
stuartharri
uniqu
ecolog
larg
human
domest
anim
popul
contribut
humananim
interfac
may
facilit
emerg
pandem
influenza
kawaoka
et
al
highli
pathogen
viru
caus
zoonot
human
infect
also
emerg
region
late
spread
number
countri
eurasia
africa
evolv
differ
lineag
longterm
surveil
establish
region
decad
result
provid
inform
evolut
anim
influenza
virus
mechan
lead
interspeci
transmiss
event
smith
et
al
vijaykrishna
et
al
challeng
remain
scientist
forecast
emerg
potenti
influenza
pandem
current
avail
control
measur
influenza
includ
vaccin
two
class
antivir
compound
ion
channel
blocker
neuraminidas
na
inhibitor
use
vaccin
control
influenza
requir
time
vaccin
product
take
month
knowledg
antigen
properti
new
circul
strain
challeng
task
annual
season
influenza
vaccin
product
suboptim
match
vaccin
strain
delay
product
could
lower
benefit
vaccin
furthermor
vaccin
may
achiev
full
protect
certain
age
group
patient
effect
vaccin
depend
immun
compet
recipi
fior
et
al
tradit
antivir
compound
ion
channel
blocker
na
inhibitor
target
function
conserv
domain
viral
protein
gener
provid
inhibitori
activ
differ
influenza
virus
includ
newli
emerg
pandem
influenza
use
treatment
prophylaxi
infect
major
challeng
use
antivir
compound
control
influenza
develop
drug
resist
difficulti
treat
patient
sever
influenza
hayden
resist
drug
class
becom
major
public
health
concern
virus
decreas
sensit
class
antivir
report
thu
urgent
need
develop
altern
influenza
treatment
novel
antivir
compound
develop
strategi
includ
improv
current
avail
drug
design
rout
deliveri
potenc
identifi
new
class
compound
target
differ
viral
protein
applic
combin
therapi
approach
remain
underexplor
may
potenti
develop
use
therapeut
intervent
one
underappreci
therapi
tradit
chines
medic
herb
histori
tradit
chines
medicin
tcm
uniqu
system
diagnosi
therapi
unlik
modern
medicin
focus
specif
target
tcm
emphas
bodi
homeostasi
yinyang
theori
exampl
kakkonto
tcm
prescript
treat
cold
influenza
shown
immunomodulatori
effect
treatment
influenza
virusinfect
mice
kakkonto
significantli
reduc
weight
loss
infect
anim
kurokawa
et
al
instead
investig
effect
tcm
crude
extract
influenza
treatment
futur
research
focu
identifi
effect
compound
isol
tcm
develop
scientif
system
platform
categor
tcm
respons
influenza
viru
infect
host
antivir
mechan
trigger
defend
cell
invad
time
virus
evolv
hijack
cellular
mechan
effici
replic
watanab
et
al
sever
influenza
lead
tissu
damag
result
viral
replic
host
immun
respons
numer
studi
highlight
possibl
target
virushost
interact
host
cellular
mechan
develop
new
regimen
influenza
therapi
ludwig
specif
block
certain
signal
pathway
led
reduct
viral
titer
well
modul
host
respons
infect
immun
modul
appli
combin
antivir
compound
dampen
tissu
damag
effect
control
infect
review
discuss
current
novel
concept
antivir
approach
influenza
point
view
target
viru
host
antivir
compound
target
function
conserv
domain
viral
protein
achiev
crossprotect
differ
strain
influenza
virus
conserv
domain
play
critic
role
viral
replic
cycl
influenza
virus
belong
famili
orthomyxovirida
singlestrand
segment
rna
genom
neg
polar
pales
shaw
eightseg
genom
influenza
viru
encod
rna
polymeras
complex
pa
nucleoprotein
np
surfac
glycoprotein
ha
na
function
receptor
bind
protein
sialidas
respect
matrix
protein
ion
channel
nonstructur
protein
pales
shaw
addit
influenza
virus
encod
mitochondriatarget
nonstructur
protein
vari
length
proapoptot
function
chen
et
al
furthermor
pax
newli
identifi
polypeptid
encod
pa
gene
respect
jagger
et
al
wise
et
al
infect
initi
attach
ha
sialic
acidcontain
glycoprotein
glycolipid
receptor
host
cell
gamblin
skehel
entri
influenza
virus
shown
occur
via
clathrindepend
endocytosi
macropinocytosi
de
vri
et
al
ha
import
host
rang
determin
influenza
virus
differ
host
show
differ
prefer
recognit
pattern
sialyl
receptor
roger
paulson
acid
environ
within
endosom
follow
viru
entri
trigger
conform
chang
ha
expos
fusion
protein
mediat
fusion
viral
envelop
endosom
membran
skehel
wiley
ion
channel
permit
proton
flow
endosom
interior
virion
disrupt
proteinprotein
interact
free
ribonucleoprotein
rnp
protein
ion
channel
also
regul
ph
transgolgi
network
prevent
prematur
conform
chang
ha
later
stage
replic
cycl
lamb
pinto
rnp
transport
nucleu
viral
mrna
synthesi
viral
genom
replic
resainfant
et
al
protein
function
rnadepend
rna
polymeras
contain
capbind
domain
pa
possess
endonucleas
activ
requir
capsnatch
viral
mrna
synthesi
newli
synthes
viral
protein
pa
np
genom
segment
packag
rnp
transport
cell
membran
final
assembl
bud
na
function
sialidas
cleav
termin
sialic
acid
residu
receptor
essenti
effici
releas
spread
virion
infect
host
cell
air
protonconduct
ion
channel
regul
virion
ph
entri
endosom
homotetram
consist
integr
membran
protein
amino
acid
amantadin
hydrochlorid
first
approv
prophylaxi
influenza
subsequ
approv
prophylaxi
treatment
influenza
infect
adamantan
deriv
amantadin
rimantadin
effect
block
ion
channel
activ
influenza
virus
exhibit
inhibit
ion
channel
influenza
b
virus
mould
et
al
mechan
action
exert
via
earli
antivir
effect
prevent
dissoci
rnp
protein
well
late
antivir
effect
caus
earli
ha
conform
chang
transgolgi
lamb
pinto
tabl
besid
lack
inhibitori
effect
influenza
b
viru
major
limit
use
amantadin
rimantadin
control
influenza
viru
infect
rapid
emerg
resist
variant
vitro
vivo
singleaminoacid
substitut
multipl
posit
residu
within
transmembran
domain
protein
confer
crossresist
amantadin
rimantadin
treatment
influenza
viru
infect
ionchannel
blocker
caus
emerg
fulli
pathogen
transmiss
resist
variant
individu
depend
detect
method
use
mutat
report
surveil
result
transmiss
variant
preval
mutat
current
use
adamantin
treatment
influenza
infect
limit
virus
sinc
resist
variant
becam
domin
deyd
et
al
furthermor
highli
pathogen
virus
evolv
differ
clade
exhibit
variabl
degre
sensit
amantadin
gutierrez
et
al
addit
newli
emerg
virus
also
resist
adamatan
due
presenc
mutat
gubareva
et
al
deriv
adamantanamin
adamantanaminoalcohol
report
greater
inhibitori
effect
amantadin
influenza
viru
replic
zoidi
et
al
deriv
spiren
guanidin
analog
undecanol
kurtz
et
al
also
identifi
stronger
ion
channelinhibit
effect
amantadin
furthermor
spiren
deriv
spiro
inhibit
variant
otherwis
confer
resist
recent
studi
transmembran
domain
tetram
complex
amantadin
rimantadin
reveal
two
potenti
inhibitor
bind
site
highaffin
bind
site
n
termin
channel
lumen
proxim
report
mutat
confer
resist
adamantan
lowaffin
bind
site
c
termin
protein
surfac
cadi
et
al
amantadin
structur
design
fit
ion
channel
futur
optim
ion
channel
blocker
base
recent
structur
inform
may
provid
new
possibl
pharmaceut
investig
cadi
et
al
sialidas
activ
na
shown
play
import
role
initi
infect
releas
spread
viral
progeni
air
matrosovich
et
al
although
ha
na
surfac
glycoprotein
subject
humor
immun
select
pressur
result
antigen
drift
presenc
conserv
residu
within
na
activ
site
across
influenza
subtyp
provid
desir
target
drug
design
von
itzstein
et
al
zanamivir
relenza
first
small
molecul
influenza
develop
structurebas
drug
design
von
itzstein
et
al
administ
via
inhal
antivir
develop
result
oral
administ
compound
oseltamivir
phosphat
tamiflu
ethyl
convert
activ
form
oseltamivir
carboxyl
acid
hepat
esteras
kim
et
al
ward
et
al
intraven
administ
compound
peramivir
carboxyl
acid
babu
et
al
zanamivir
oseltamivir
approv
prophylaxi
therapi
influenza
b
sinc
usa
subsequ
countri
peramivir
current
phase
iii
clinic
trial
usa
avail
korea
japan
na
inhibitor
current
predomin
antivir
drug
use
treatment
prophylaxi
influenza
oseltamivir
frequent
use
zanamivir
clinic
due
oral
rout
administr
also
approv
use
wider
age
group
includ
children
year
old
na
inhibitor
analog
sialic
acid
mechan
antivir
activ
competit
natur
ligand
block
enzym
activ
site
na
inhibitor
effect
influenza
b
virus
even
differ
na
subtyp
sinc
conserv
enzym
site
rel
conserv
subtl
structur
differ
identifi
russel
et
al
specif
differ
na
subtyp
influenza
viru
group
base
phylogenet
analysi
group
contain
group
contain
subtyp
compar
group
na
group
na
possess
extend
caviti
due
differ
amino
acid
residu
within
residu
russel
et
al
extend
caviti
provid
new
insight
na
inhibitor
design
rudrawar
et
al
interestingli
viru
report
lack
resist
viral
variant
isol
vitro
studi
serial
passag
presenc
na
inhibitor
also
aris
patient
treat
na
inhibitor
gubareva
mckimmbreschkin
due
differenti
interact
oseltamivir
zanamivir
conserv
residu
na
enzym
site
mutat
confer
resist
oseltamivir
often
confer
resist
zanamivir
laninamivir
hayden
oseltamivirresist
variant
emerg
therapeut
usag
clinic
deriv
resist
zanamivir
occur
lower
frequenc
hurt
et
al
furthermor
clinicallyderiv
na
mutat
confer
resist
oseltamivir
subtypespecif
na
inhibitor
structur
similar
natur
ligand
sialic
acid
thought
mutat
conserv
na
residu
confer
drug
resist
would
also
decreas
na
activ
stabil
compromis
viral
fit
other
attempt
understand
effect
differ
na
mutat
fit
includ
pathogen
transmiss
potenti
resist
variant
abe
et
al
kiso
et
al
yen
et
al
among
na
mutat
confer
resist
na
inhibitor
na
mutat
number
extens
studi
date
due
signific
season
highli
pathogen
recent
viru
mutat
first
report
clinic
trial
among
patient
receiv
oseltamivir
gubareva
et
al
gener
detect
low
frequenc
among
commun
isol
prior
influenza
season
monto
et
al
sheu
et
al
howev
increas
number
season
influenza
virus
encod
mutat
number
emerg
northern
europ
late
subsequ
spread
global
result
domin
variant
wildtyp
viru
dharan
et
al
lackenbi
et
al
detail
mechan
enabl
transmiss
variant
still
research
bloom
et
al
rameixwelti
et
al
na
mutat
confer
resist
oseltamivir
peramivir
zanamivir
laninamivir
abrisban
virus
na
mutat
resist
oseltamivir
remain
larg
sensit
zanamivir
channel
blocker
howev
dual
resist
oseltamivir
channel
blocker
detect
increas
rate
among
season
influenza
virus
isol
detect
rate
report
us
center
diseas
control
prevent
cdc
season
season
replac
newli
emerg
viru
sheu
et
al
interestingli
dualresist
strain
emerg
genet
reassort
acquir
gene
clade
viru
mutat
confer
resist
amantadin
clade
virus
alreadi
carri
na
mutat
sheu
et
al
mention
previous
virus
emerg
carri
mutat
protein
confer
resist
amantadin
rimantadin
dualresist
virus
acquir
na
mutat
confer
resist
na
inhibitor
identifi
isol
test
suscept
hurt
et
al
na
mutat
frequent
identifi
mutat
among
virus
exhibit
resist
na
inhibitor
variant
carri
na
mutat
also
report
hurt
et
al
recent
studi
character
fit
transmiss
potenti
virus
carri
na
mutat
show
variabl
find
transmiss
studi
anim
support
compar
slightli
delay
transmiss
potenti
variant
duan
et
al
kiso
et
al
memoli
et
al
seibert
et
al
wong
et
al
longact
na
inhibitor
laninamivir
approv
japan
sinc
treatment
influenza
b
prodrug
laninamivir
octano
process
laninamivir
lung
administ
inhal
kubo
et
al
tabl
singl
nasal
administr
lead
long
retent
drug
lung
provid
long
last
antiinfluenza
activ
vivo
yamashita
et
al
laninamivir
zanamivir
possess
group
shown
result
greater
potenc
na
subtyp
caviti
form
vavricka
et
al
clinic
trial
report
compar
effect
laninamivir
versu
na
inhibitor
viru
season
influenza
viru
influenza
b
viru
ikematsu
kawai
shobugawa
et
al
press
besid
novel
na
inhibitor
improv
rout
administr
intraven
zanamivir
deliveri
test
emerg
investig
new
drug
eind
scheme
usa
namedpati
program
countri
depend
regul
tabl
peramivir
also
administ
hospit
adult
children
sever
viral
pneumonia
eind
emerg
use
author
eua
usa
pandem
hernandez
et
al
sorbello
et
al
yu
et
al
addit
doubleor
triplecombin
chemotherapi
oseltamivir
adamantan
ribavirin
shown
addit
synergist
effect
vitro
anim
model
hoop
et
al
ilyushina
et
al
ilyushina
et
al
nguyen
et
al
smee
et
al
combin
therapi
may
also
play
role
limit
emerg
drugresist
virus
recent
clinic
trial
appli
combin
therapi
oseltamivir
zanamivir
show
greater
protect
monotherapi
season
influenza
mainli
infect
human
duval
et
al
similarli
retrospect
studi
compar
effect
oseltamivir
monotherapi
triplecombin
treatment
oseltamivir
amantadin
ribavirin
patient
requir
ventil
support
report
compar
clinic
outcom
two
group
studi
requir
understand
effect
combin
therapi
human
role
limit
emerg
resist
variant
bdribofuranosyl
nucleosid
analog
exhibit
broad
rang
antivir
activ
rna
dna
virus
de
clercq
sidwel
et
al
process
cellular
adenosin
kinas
ribavirin
monophosph
rmp
follow
subsequ
phosphoryl
dior
triphosph
rtp
form
graci
cameron
major
antivir
activ
confer
rmp
form
structur
similar
cellular
inosin
monophosph
imp
rmp
imp
therefor
compet
imp
dehydrogenas
impdh
activ
site
lead
deplet
cellular
gtp
pool
tabl
deplet
gener
effect
viral
host
rna
dna
protein
synthesi
consid
caus
ribavirin
broad
antivir
activ
differ
rna
dna
virus
de
clercq
graci
cameron
nucleosid
analog
ribavirin
may
also
directli
interact
viral
polymeras
influenza
virus
rtp
shown
interact
rna
polymeras
cellfre
system
exhibit
competit
inhibit
gtp
atp
utp
ctp
eriksson
et
al
howev
higher
concentr
rtp
requir
fulli
inhibit
influenza
viru
rna
elong
competit
gtp
atp
suggest
rtp
incorpor
influenza
viral
genom
parker
mechan
may
increas
errorpron
replic
lead
errorcatastroph
reduct
yield
infecti
viru
vignuzzi
et
al
despit
report
broad
vitro
antivir
activ
ribavirin
clinic
applic
influenza
limit
due
toxic
limit
evid
clinic
efficaci
variabl
result
report
trial
use
oral
aerosol
ribavirin
influenza
b
patient
patient
receiv
intraven
ribavirin
eind
scheme
riner
et
al
ribavirin
avail
oral
form
influenza
treatment
mexico
eichelberg
et
al
tabl
combin
therapi
use
ribavirin
pegyl
interferonalpha
establish
earli
becom
standard
treatment
chronic
hepat
c
viru
hcv
infect
adult
de
clercq
treatment
sever
respiratori
syncyti
viru
rsv
infect
use
aerosol
ribavirin
approv
although
clinic
benefit
still
debat
de
clercq
influenza
ribavirin
monotherapi
test
clinic
trial
eind
sever
infect
result
studi
inconclus
due
small
sampl
size
differ
treatment
dose
durat
potenti
clinic
benefit
ribavirin
treatment
influenza
infect
therefor
remain
clarifi
importantli
resist
ribavirin
report
hcv
rsv
influenza
virus
favipiravir
pyrazin
deriv
first
identifi
inhibit
influenza
b
c
virus
vitro
influenza
viru
mous
model
furuta
et
al
action
mediat
via
process
form
ribofuranosyl
phosphat
includ
monophosph
triphosph
form
triphosph
form
misrecogn
influenza
viru
polymeras
purin
nucleotid
rna
elong
inhibit
polymeras
activ
furuta
et
al
unlik
ribavirin
host
enzym
differenti
favipiravir
phosphoryl
form
natur
nucleotid
favipiravir
therefor
show
littl
inhibitori
effect
host
cell
less
cytotox
ribavirin
furuta
et
al
antivir
activ
vari
depend
host
cell
use
differ
uptak
effici
andor
effect
convers
favipiravir
ribofuranosyl
phosphat
hostcel
enzym
may
determin
antivir
activ
furuta
et
al
synergist
effect
oseltamivir
favipiravir
report
mice
influenza
viru
infect
besid
influenza
viru
favipiravir
inhibit
rna
virus
includ
arenavirus
bunyavirus
west
nile
viru
alphavirus
polioviru
rhinovirus
rsv
favipiravir
exhibit
inhibitori
effect
dna
virus
includ
herp
simplex
human
cytomegaloviru
adenovirus
valu
lm
furuta
et
al
ribavirin
shown
inhibitori
effect
dna
virus
possibl
dna
viral
polymeras
differenti
favipiravir
better
ribavirin
limit
resist
favipiravir
report
resist
variant
detect
serial
passag
influenza
viru
furuta
et
al
favipiravir
began
phase
iii
clinic
trial
japan
octob
phase
ii
clinic
trial
usa
februari
may
therefor
see
increas
use
favipiravir
near
futur
treatment
influenza
influenza
polymeras
complex
heterotrim
form
pa
protein
conserv
pa
c
term
n
term
bind
domain
also
explor
target
influenza
antivir
da
et
al
ghanem
et
al
peptid
deriv
nterm
shown
bind
pa
inhibit
viral
replic
transcript
ghanem
et
al
wunderlich
et
al
combin
knowledg
deriv
crystal
structur
complex
et
al
obayashi
et
al
studi
provid
first
step
identifi
design
small
molecul
specif
disrupt
proteinprotein
interact
synthesi
influenza
genom
vrna
crna
occur
de
novo
mrna
synthesi
viru
protein
product
requir
hostderiv
mrnaderiv
cap
primer
da
et
al
capbind
domain
influenza
polymeras
identifi
within
guilligay
et
al
endonucleas
capsnatch
activ
confer
n
terminu
pa
dia
et
al
furthermor
compound
inhibit
endonucleas
capsnatch
activ
report
tomassini
et
al
tabl
knowledg
catalyt
site
dia
et
al
yuan
et
al
two
recent
studi
solv
cocryst
structur
pa
endonucleas
domain
known
predict
inhibitor
duboi
et
al
kowalinski
et
al
togeth
vitro
assay
measur
antiendonucleas
antivir
activ
new
insight
propos
develop
potenti
pa
endonucleas
inhibitor
duboi
et
al
kowalinski
et
al
screen
chemic
librari
use
cellbas
influenza
infect
assay
three
laboratori
independ
identifi
smallmolecul
compound
nucleozin
induc
np
oligom
format
gerritz
et
al
kao
et
al
su
et
al
tabl
inhibitori
effect
associ
inhibit
np
transport
cytoplasm
nucleu
kao
et
al
resolut
crystal
structur
nucleozin
analog
bound
np
reveal
np
dimer
format
occur
via
two
ligand
bind
site
np
monom
hexamer
structur
also
observ
consist
three
np
dimer
gerritz
et
al
analog
nucleozin
identifi
possess
potent
inhibitori
effect
vitro
vivo
howev
resist
develop
vitro
passag
kao
et
al
resist
nucleozin
also
observ
among
natur
circul
influenza
strain
includ
viru
possess
mutat
ligandbind
pocket
gerritz
et
al
kao
et
al
su
et
al
studi
support
concept
np
potenti
target
novel
antivir
optim
nucleozin
analog
requir
increas
specif
minim
drug
resist
influenza
ha
mediat
receptor
bind
membran
fusion
activ
via
variabl
globular
head
region
conserv
stem
region
respect
structurebas
design
result
small
molecul
inhibit
fusogen
conform
chang
ha
howev
compound
present
provid
protect
across
rang
differ
ha
subtyp
bodian
et
al
vanderlinden
et
al
howev
except
arbidol
dimethylamino
methyl
phenylthio
methyl
hydrochlorid
monohydr
licens
russia
treatment
influenza
b
virus
leneva
et
al
arbidol
exert
immunemodulatori
effect
well
broad
antivir
activ
influenza
viru
rsv
rhinovirus
coxsacki
viru
hcv
chikungunya
viru
delogu
et
al
shi
et
al
mechan
antivir
activ
influenza
demonstr
identif
resist
variant
singl
amino
acid
chang
affect
ha
fusion
ph
conform
chang
leneva
et
al
tabl
altern
approach
made
use
comput
design
protein
inhibitor
target
ha
stem
region
block
fusion
protein
inhibitor
improv
crossreact
bind
affin
group
ha
achiev
screen
dnaencod
librari
protein
variant
use
yeast
surfac
display
follow
deep
sequenc
whitehead
et
al
addit
compound
mention
target
fusion
mechan
inhibitor
develop
target
ha
includ
cyanobacteriumderiv
protein
cyanovirinn
bind
highmannos
structur
ha
block
viral
entri
smee
et
al
peptid
deriv
fibroblast
signal
sequenc
possess
inhibitori
effect
viral
attach
cell
jone
et
al
nitazoxanid
target
posttransl
stage
block
ha
matur
transport
rossignol
et
al
highmolecularweight
sulphat
polysaccharid
iotacarrageenan
deriv
red
seawe
inhibit
viral
spread
well
entri
leibbrandt
et
al
recent
studi
identifi
natur
occur
human
antibodi
vaccin
expos
individu
bind
differ
ha
type
crossreact
antibodi
possess
neutral
activ
inhibit
ha
fusogen
conform
chang
corti
et
al
ekiert
et
al
sui
et
al
throsbi
et
al
target
ha
globular
head
prevent
viral
attach
cell
yoshida
et
al
defin
hafab
interact
resolut
crystal
structur
reveal
seri
conserv
epitop
within
ha
stalk
region
corti
et
al
ekiert
et
al
sui
et
al
antibodi
test
vitro
mice
ferret
exhibit
signific
protect
upon
challeng
use
differ
viral
subtyp
friesen
et
al
koudstaal
et
al
use
adopt
immunotherapi
may
consid
pandem
prepared
crossprotect
achiev
regardless
subtyp
emerg
strain
research
ongo
identifi
immun
determin
lead
crossreact
antibodi
respons
target
domain
wang
pales
multifunct
protein
interact
mani
viral
host
protein
replic
cycl
hale
et
al
among
multipl
function
essenti
abil
antagon
type
interferon
respons
achiev
sever
mechan
includ
interact
prevent
rigi
activ
bind
cpsf
poli
bind
protein
ii
limit
export
cellular
mrna
directli
bind
inhibit
activ
pkr
bind
doublestrand
rna
detect
oligoadenyl
synthas
oa
gack
et
al
hale
et
al
yeastbas
assay
develop
screen
small
molecul
activ
basu
et
al
four
compound
found
possess
antiinfluenza
activ
specif
show
reduct
viral
protein
synthesi
viral
rna
product
tabl
demonstr
specif
influenza
viru
rsv
effect
interferoncompet
cell
deriv
one
compound
synthes
jablonski
et
al
walkiewicz
et
al
one
show
antiinfluenza
effect
depend
host
rnase
l
activ
walkiewicz
et
al
result
suggest
potenti
target
novel
influenza
viru
inhibitor
earliest
step
viral
replic
cycl
influenza
viru
bind
host
cell
interact
viral
ha
terminallylink
sialyl
receptor
present
cell
surfac
remov
sialic
acid
cell
surfac
therefor
approach
util
disrupt
virushost
interact
tabl
sialidas
fusion
construct
design
remov
sialic
acid
cell
surfac
compos
catalyt
domain
sialidas
bacteria
actinomyc
viscosu
human
respiratori
epitheliumanchor
domain
fuse
cterminu
well
toler
human
immun
system
viscosu
common
oral
bacterium
human
respiratori
epitheliumanchor
domain
contain
heparinbind
sequenc
increas
retent
time
drugpot
malakhov
et
al
sialidas
activ
remov
residu
recogn
avian
human
influenza
virus
respect
demonstr
prophylact
therapeut
effect
viru
infect
mice
belser
et
al
treatment
lead
desialyl
human
lung
bronchial
tissu
ex
vivo
well
primari
pneumocyt
airway
epitheli
cell
therebi
inhibit
broad
spectrum
influenza
virus
includ
newli
emerg
viru
oseltamivirresist
virus
trianabaltz
et
al
b
also
effect
human
parainfluenza
virus
vitro
vivo
moscona
et
al
reduc
influenza
viru
infect
use
remov
sialic
acid
cell
surfac
rais
concern
potenti
exposur
cryptic
receptor
might
allow
bacteri
adher
increas
suscept
bacteri
infect
zhang
howev
recent
data
suggest
treatment
enhanc
colon
streptococcu
pneumonia
either
vitro
vivo
hedlund
et
al
unlik
na
blocker
target
viru
respiratori
epitheli
cell
host
recent
studi
demonstr
influenza
viru
variant
select
serial
passag
presenc
attenu
possess
unstabl
resist
phenotyp
influenza
b
virus
regain
sensit
drug
remov
trianabaltz
et
al
thu
develop
resist
futur
could
low
also
proven
safe
mice
expos
high
concentr
mgkg
day
drypowd
formul
well
toler
dose
level
bodi
size
food
consumpt
paramet
affect
human
intern
phase
ii
clinic
trial
conduct
involv
patient
influenza
b
viru
infect
signific
decreas
viral
shed
seen
patient
receiv
lowdos
treatment
three
consecut
day
advers
effect
report
note
influenza
ha
glycoprotein
function
bind
receptor
fusion
protein
compos
two
subunit
cleav
host
proteas
precursor
skehel
waterfield
cleavag
function
activ
viru
infect
import
pathogen
human
avian
host
steinhauer
function
ha
abl
undergo
conform
chang
lowph
endosom
environ
induc
membran
fusion
follow
infect
skehel
wiley
two
proteas
human
airway
trypsinlik
proteas
hat
transmembran
proteas
serin
member
cleav
monobas
cleavag
site
bottcher
et
al
express
two
proteas
mdck
cell
support
propag
season
influenza
virus
absenc
trypsin
bottcher
et
al
recent
identifi
found
similar
role
activ
ha
chaipan
et
al
ha
highli
pathogen
influenza
virus
possess
multibas
proteas
cleavag
site
cleav
furin
relat
cellular
proteas
locat
transgolgi
apparatu
stienekegrob
et
al
howev
acquisit
multibas
cleavag
site
within
ha
alway
transform
lowpathogen
viru
highli
pathogen
one
stech
et
al
earlier
report
describ
proteas
inhibitor
mean
suppress
replic
influenza
virus
zhirnov
et
al
tabl
recent
peptidemimet
proteas
inhibitor
hat
demonstr
block
viral
replic
vitro
inhibit
ha
cleavag
cell
surfac
within
cell
respect
bottcherfriebertshaus
et
al
improv
select
potenc
achiev
incorpor
synthet
amino
acid
residu
norvalin
proteas
inhibitor
sielaff
et
al
use
singlestrand
dnalik
antisens
agent
block
express
also
inhibit
influenza
viru
infect
human
airway
epitheli
cell
studi
highlight
proteas
inhibitor
altern
therapeut
approach
addit
influenza
recent
report
also
demonstr
proteas
inhibitor
potenti
therapeut
agent
respiratori
virus
includ
sarscoronaviru
matsuyama
et
al
thu
may
wider
applic
futur
like
rna
virus
influenza
virus
take
advantag
activ
cellular
signal
support
replic
novel
antivir
drug
disrupt
hijack
signal
event
could
therefor
consid
develop
rafmekerk
signal
pathway
belong
mitogenactiv
protein
kinas
mapk
cascad
consist
seri
serinethreonin
kinas
cascad
import
pathway
convert
ligat
extracellular
molecul
intracellular
signal
control
cell
prolifer
differenti
surviv
su
karin
activ
trigger
gproteincoupl
receptor
receptor
tyrosin
kinas
lead
stepwis
phosphoryl
activ
raf
kinas
serin
threonin
kinas
particip
sequenti
cascad
activ
turn
activ
numer
stimuli
includ
growth
factor
hormon
cytokin
trigger
pathway
activ
mapk
cascad
recogn
hallmark
signal
pathway
activ
influenza
b
viru
pleschka
et
al
includ
highli
pathogen
avian
droebner
et
al
specif
inhibitor
block
cascad
mapkerk
kinas
mek
level
result
nuclear
retent
viral
rnp
complex
impair
function
nuclear
export
protein
suppress
viru
product
pleschka
et
al
tabl
studi
suggest
activ
mapk
cascad
lead
effici
rnp
export
well
viru
product
achiev
accumul
viral
ha
cell
surfac
result
enhanc
viral
polymeras
activ
marjuki
et
al
exhibit
high
antivir
activ
low
cytotox
vitro
vivo
droebner
et
al
pleschka
et
al
make
promis
drug
clinic
investig
next
import
phase
test
effici
mapk
cascad
inhibitor
block
influenza
viru
replic
human
date
evalu
mek
inhibitor
virusinfect
mice
limit
administ
aerosol
rout
droebner
et
al
haasbach
et
al
commonli
employ
human
mek
inhibitor
use
clinic
trial
cancer
patient
becom
commerci
avail
research
warrant
nfjb
signal
anoth
import
pathway
commonli
activ
influenza
viru
infect
upon
recognit
pathogen
infect
tissu
damag
nfjb
pathway
strongli
activ
cellular
pattern
recognit
receptor
includ
tolllik
receptor
multipl
cytosol
receptor
retino
induc
gene
rigi
like
helicas
nod
famili
protein
nfjbrespons
gene
affect
divers
array
cellular
process
includ
apoptosi
cell
surviv
often
directli
control
cours
infect
upregul
varieti
antivir
gene
iversen
paludan
influenza
viru
infect
activ
nfjb
pathway
activ
result
product
variou
cytokin
julkunen
et
al
nfjb
known
key
regul
cytokin
express
includ
interferon
ifn
b
pahl
ifnb
initi
type
ifn
defens
program
mediat
antivir
activ
wolff
ludwig
bind
cellsurfac
type
ifn
receptor
activ
jakstat
pathway
control
express
variou
antivir
gene
platania
although
nfjb
pathway
mediat
antivir
activ
influenza
virus
also
evolv
evad
control
activ
nfjb
exampl
viral
protein
antagon
nfjb
pathway
ifnb
induct
signal
wang
et
al
note
novel
smallmolecul
inhibitor
restor
interferoninduc
antivir
state
number
recent
studi
babu
et
al
jablonski
et
al
walkiewicz
et
al
suggest
high
potenti
inhibitor
viral
ifn
antagonist
antivir
drug
influenza
viru
infect
also
induc
express
trail
fasl
stimul
caspas
action
wurzer
et
al
wurzer
et
al
play
major
role
nuclear
disassembl
cleav
cellular
protein
increas
diffus
limit
nuclear
membran
faleiro
lazebnik
nuclear
retent
viral
rnp
complex
observ
inhibitor
caspas
nfjb
appli
infect
cell
suggest
caspas
activ
crucial
viral
rnp
traffick
mazur
et
al
wurzer
et
al
hand
influenza
virus
could
also
induc
express
suppressor
cytokin
via
nfjb
signal
induct
lead
inhibit
ifninduc
activ
jakstat
pathway
control
express
antivir
ifnstimul
gene
isg
kubo
et
al
tabl
nfjb
novel
therapeut
target
influenza
therapi
variou
studi
shown
inhibit
nfjb
pathway
reduc
viral
titer
exampl
acetylsalicyl
acid
asa
commonli
known
aspirin
inhibitor
inhibit
influenza
viru
replic
vitro
vivo
gener
resist
strain
multipassag
experi
mazur
et
al
howev
caution
aspirin
link
rey
syndrom
children
influenza
eyer
et
al
starko
promin
system
symptom
adult
viru
infect
compar
receiv
amantadin
alon
younkin
et
al
recent
pyrrolidin
dithiocarbam
pdtc
inhibitor
nfjb
pathway
shown
increas
surviv
mice
wiesen
et
al
other
shown
treatment
inhibitor
rafmekerk
cascad
nfjb
significantli
reduc
viru
titer
cytokin
express
vitro
vivo
pinto
et
al
also
suggest
cellular
factor
activ
respons
influenza
viru
infect
play
import
role
regul
viru
replic
ehrhardt
et
al
although
immun
system
provid
necessari
respons
infect
may
alway
success
elimin
threat
pose
influenza
virus
virus
may
directli
cytopath
other
highli
pathogen
viru
caus
cytokin
dysregul
upregul
proinflammatori
cytokin
lead
fatal
outcom
use
immunomodul
return
immun
respons
homeostasi
therefor
promis
strategi
deal
deleteri
host
respons
trigger
virus
compon
arachidonicacid
cascad
thought
involv
inflamm
immun
respons
therefor
target
antiinflammatori
drug
note
shown
asa
block
nfb
activ
activ
cox
inhibit
influenza
viru
replic
mazur
et
al
howev
treatment
indomethacin
pure
cox
inhibitor
inhibit
fail
show
effect
viru
replic
therefor
conclud
asa
block
influenza
viru
replic
via
inhibit
nfb
signal
mazur
et
al
unlik
induc
constitut
express
normal
bodi
tissu
includ
bronchiolar
alveolar
epitheli
cell
pulmonari
alveolar
macrophag
rat
nonhuman
primat
ermert
et
al
khan
et
al
wilborn
et
al
involv
import
physiolog
function
vasodilat
bronchodil
surfact
synthesi
brannon
et
al
treatment
indomethacin
therefor
block
activ
activ
physiolog
import
thu
perhap
lead
detriment
effect
virusinfect
cell
fact
vivo
studi
demonstr
defect
led
opposit
effect
virusinfect
mice
defici
detriment
defici
improv
surviv
carey
et
al
shown
play
regulatori
role
induct
proinflammatori
respons
viru
select
inhibitor
commonli
use
treat
rheumatoid
arthriti
osteoarthr
acut
pain
immunomodulatori
effect
suppress
hypercytokin
induct
infect
lee
et
al
recent
studi
demonstr
select
inhibitor
suppress
viru
replic
vitro
suggest
viral
replic
depend
activ
signal
pathway
anoth
studi
show
treatment
virusinfect
mice
inhibitor
celecoxib
combin
mesalazin
zanamivir
significantli
improv
surviv
zheng
et
al
studi
highlight
possibl
target
regul
viru
replic
host
immun
respons
develop
new
treatment
regimen
tabl
studi
highlight
role
resolut
latestag
inflamm
chan
moor
fukunaga
et
al
inhibit
may
detriment
effect
treat
acut
lung
injuri
lukkarinen
et
al
futur
work
aim
identifi
host
factor
downstream
pathway
crucial
viru
replic
may
lead
separ
antivir
effect
induct
mediat
import
resolut
inflamm
recoveri
lung
injuri
ligand
famili
gproteincoupl
receptor
gpcr
differenti
express
variou
cell
type
bind
receptor
enabl
control
varieti
cellular
activ
includ
adhes
migrat
cytokin
secret
barrier
integr
play
import
role
inflamm
immun
rivera
et
al
aalr
broadspectrum
agonist
receptor
shown
impair
activ
dendrit
cell
downmodul
influenza
virusspecif
tcell
respons
dampen
releas
proinflammatori
cytokin
lead
decreas
lung
injuri
influenza
viru
infect
marsolai
et
al
tabl
interestingli
although
signific
cell
suppress
product
protect
antibodi
infect
mice
affect
aalr
treatment
differ
action
antivir
drug
oseltamivir
reduct
tissu
damag
result
reduc
viral
burden
aalr
use
treat
influenza
infect
combin
antivir
promot
viral
clearanc
well
clinic
cours
walsh
et
al
data
indic
aalr
may
use
drug
influenza
treatment
either
alon
combin
dampen
cytokin
respons
reduc
lung
injuri
maintain
benefit
protect
immun
respons
although
signal
appear
promis
therapeut
target
also
mediat
variou
kind
cellular
activ
develop
agonist
target
specif
receptor
therefor
need
recent
studi
teijaro
et
al
demonstr
treatment
receptor
specif
agonist
significantli
reduc
cytokin
chemokin
respons
associ
influenza
virusinduc
injuri
vivo
howev
unlik
aalr
impair
dendrit
cell
activ
enabl
initi
tcell
respons
tabl
enhanc
innat
immun
respons
first
line
defens
viral
infect
could
also
consid
altern
therapeut
approach
influenza
natur
killer
nk
cell
key
effector
innat
immun
keep
infect
control
earli
phase
kill
virusinfect
cell
howev
influenza
viru
could
evad
innat
immun
defens
infect
nk
cell
inhibit
cytotox
activ
mao
et
al
human
gammadelta
cd
cell
share
characterist
cell
nk
cell
antigenpres
cell
mediat
innat
adapt
respons
infect
born
et
al
brand
et
al
unlik
nk
cell
cd
cell
suscept
influenza
viru
infect
expans
cd
cell
may
therefor
consid
altern
therapeut
approach
tabl
cd
cell
constitut
lymphocyt
peripher
blood
human
cell
receptor
major
cd
cell
peripher
blood
lymphoid
organ
card
egan
isopentenyl
pyrophosph
ipp
expand
cell
shown
specif
cytotox
toward
influenza
virusinfect
human
monocytederiv
macrophag
dosedepend
manner
expand
cell
also
demonstr
antivir
activ
season
avian
influenza
virus
aminobisphosphon
pamidron
pam
also
recent
shown
effect
similar
ipp
result
kill
infect
cell
inhibit
influenza
viru
replic
cell
pam
treatment
influenzainfect
human
mice
also
demonstr
benefit
expand
popul
cell
tu
et
al
expans
cell
ipp
pam
may
thu
provid
novel
safe
approach
influenza
therapi
enhanc
immun
system
first
line
defens
peroxisom
proliferatoractiv
receptor
ppar
nuclear
hormon
receptor
categor
three
subtyp
b
c
subtyp
express
divers
array
cell
type
activ
differ
ligand
kliewer
et
al
pparc
express
adipos
tissu
monocyt
macrophag
play
role
glucos
metabol
adipocyt
differenti
tontonoz
et
al
numer
studi
found
pparc
may
involv
regul
cytokin
product
activ
pparc
receptor
ligand
inhibit
product
tnfa
proinflammatori
cytokin
mani
cell
type
monocyt
lymphocyt
transrepress
nfjb
clark
et
al
jiang
et
al
pascual
et
al
tabl
recent
studi
treatment
mice
pparc
agonist
pioglitazon
influenza
viru
challeng
led
suppress
product
herold
et
al
reduct
infiltr
tnfinosproduc
monocyt
lung
improv
surviv
aldridg
et
al
result
suggest
ppar
agonist
may
use
modul
immun
respons
influenza
viru
infect
reduc
immunopatholog
tissu
damag
statin
wide
use
treat
high
blood
cholesterol
level
revers
competit
inhibit
activ
coenzym
hmgcoa
reductas
reduc
synthesi
cholesterol
mevalon
chong
et
al
addit
lipidlow
activ
statin
exert
immunomodulatori
effect
tabl
suppress
mhcii
express
induc
ifnc
without
modul
constitut
mhcii
express
reduc
induc
express
ciita
gener
mhcii
control
inhibit
activ
ciita
promot
iv
inhibit
induc
express
mhcii
suppress
activ
lymphocyt
reduc
inflammatori
respons
kwak
et
al
statin
also
anoth
immunomodulatori
mechan
via
interact
lymphocyt
functionassoci
glycoprotein
b
integrin
famili
weitzschmidt
et
al
activ
engag
tcell
chemokin
receptor
bind
intracellular
adhes
drive
variou
downstream
activ
includ
lymphocyt
recircul
leukocyt
extravas
carlo
harlan
therapeut
potenti
statin
influenza
therapi
recent
demonstr
studi
show
significantli
reduc
risk
death
influenza
patient
receiv
statin
frost
et
al
kwong
et
al
howev
retrospect
studi
potenti
bias
patient
treat
statin
acquir
influenza
benefici
effect
statin
recent
challeng
benefici
effect
influenza
patient
observ
fleme
et
al
viasu
et
al
investig
carri
especi
identifi
possibl
benefici
effect
initi
statin
near
onset
influenza
ill
time
hospit
molecular
mechan
statin
activ
influenza
infect
also
remain
poorli
understood
one
possibl
inhibit
deplet
cholesterol
biosynthesi
disrupt
structur
membraneresid
lipid
raft
result
loos
interact
microlipid
domain
activ
raf
mekerk
signal
cascad
requir
effici
nuclear
cytoplasm
rnp
local
trigger
accumul
influenza
ha
cell
membran
thu
close
associ
lipid
raft
statin
treatment
might
interfer
chain
event
lower
cholesterol
biosynthesi
influenza
infect
impair
product
infecti
viru
influenza
viru
infect
human
lead
mild
sever
ill
result
viral
replic
host
immun
respons
earli
treatment
na
inhibitor
ion
channel
blocker
current
mainstay
patient
manag
howev
respons
antivir
therapi
variabl
develop
drug
resist
rais
public
health
concern
identif
resist
variant
transmiss
pathogen
compar
wildtyp
counterpart
highlight
need
improv
design
na
inhibitor
develop
new
class
antivir
compound
review
discuss
approach
develop
control
influenza
viru
infect
includ
improv
design
potenc
rout
deliveri
exist
inhibitor
identifi
novel
class
compound
biomolecul
inhibit
viru
replic
block
virushost
interact
reduc
viral
replic
effici
modul
host
immun
respons
allevi
tissu
damag
combin
therapi
current
research
aim
improv
exist
therapi
target
either
influenza
virus
cellular
factor
affect
viral
replic
host
innat
immun
respons
summar
tabl
control
influenza
best
target
viru
host
target
viru
provid
specif
direct
inhibitori
effect
target
host
certainli
provid
advantag
includ
lower
likelihood
drug
resist
immunomodulatori
effect
may
decreas
tissu
damag
novel
approach
immunomodulatori
antivir
effect
therefor
deserv
special
attent
furthermor
applic
antivir
drug
combin
immunomodulatori
agent
provid
promis
direct
seen
recent
vivo
studi
zheng
et
al
walsh
et
al
preclin
clinic
trial
need
studi
underli
mechan
action
confirm
benefici
effect
influenza
human
